Author | Lisa M. Holle, PharmD, BCOP, FHOPA


New Drug Review: Erdafitinib

July 17, 2019

First oral drug for advanced or metastatic bladder cancer.

New Drug Review: Spravato

June 13, 2019

Both responder and remitter patients experienced a statistically significant longer time to relapse with esketamine compared to the placebo

Apalutimide for Prostate Cancer: What to Know

April 04, 2018

FDA approves apalutamide for castration-resistant prostate cancer.

FDA Approves Emicizumab-kxwh for Hemophilia A

January 04, 2018

Emicizumab-kxwh brings together factors IXa and X to restore the function of the missing activated factor VIII and the blood clotting process.